Although we were not able to find any important correlations with the time progression of FSGS in that study, data from both studies suggest some kind of disequilibrium between endothelin 1 and anti-ETAR in FSGS patients. This evidence concerns the gene EDN1 and focal segmental glomerulosclerosis.